Kerecis has developed the unique, patented Kerecis™ Omega3 fish-skin acellular dermal matrix transplantation technology, where complete acellular fish skin is used for tissue regeneration by transplantation. The Kerecis™ Omega3 transplantation technology is used to reconstruct the skin in chronic wounds, for hernia repair, breast reconstruction and for dura restoration. Other tissue-transplant products are based on tissues of human and porcine origin. The Kerecis™ Omega3 fish skin offers improved economics and clinical performance, as well as reduced disease transfer risk and no cultural constraints on usage. Kerecis extracts proprietary mOmega3™ fatty acids from fish skin and incorporates in patented dermatological skin treatment products that are indicated to treat the symptoms of various skin inflammation diseases.

The Omega3 fish-skin acellular dermal matrix transplantation technology has application in wound care and surgical applications. Every year about 34.5 million chronic wounds are treated globally. In the chronic wound the balance between production and degradation of molecules is lost and degradation plays too large a role. Kerecis helps wound regain balance and heal. Globally millions of dura repair, hernia repair and breast reconstruction operations are performed annually. Complications may arise post-operatively, including rejection of the mesh that is used to repair the defect. Kerecis provides a unique reconstruction material that provides strong repair hold is re-vascularized and gradually is replaced by the patient's own tissue.
Damage to the intercelluar material of the skin's corneal layer causes dryness and inflammation. mOmega3™ are proprietary, fish-sourced fatty acids, that restore the health of the corneal layer of the skin in a natural manner benefitting a multitude of abnormal skin conditions such as psoriasis, eczema, dermatitis, keratosis pilaris and pseudofolliculitis.